November 13-15, 2018

Boston, MA, USA

Twitter logo for website footers 2

Optimize complex discovery, biomarker validation & clinical translation to develop complement inhibition for rare and common diseases

With the only approved complement therapeutic, Soliris, on the market for over a decade, the industry is overflowing with companies in clinical translation in a race for the next approval. The 2nd Complement-based Drug Development Summit encapsulates this excitement and provides one platform for every leading complement company to network and learn in an effort to overcome common challenges including:

  • Create Translatable Complement Assays: Explore the need for a standardized assay to minimize variation between labs and accurately determine clear and reliable clinical comparisons.

  • Identify which Common Indication will Benefit Most: As the industry delves into targeting common disease indications, this meeting will explore which indication has the most potential for clinical success.

  • Identify Novel Biomarkers to Improve Efficacy Assessments: Identify biomarkers that are driving disease and indicating complement activation to allow accurate measurements of efficacy and endpoints.

  • The Role of Complement in the CNS: Understand the biology of complement in the CNS and explore which complexes can be targeted to treat neurological disorders.

Last year we brought together the complement community to explore the potential of complement inhibition in rare diseases. This year we are getting bigger and better by exploring the wider potential of complement therapy in rare and common disease indications.

Attend this meeting to gain clear clinical understanding of the potential role of complement in common indications and identify which indication will be the next big opportunity for complement-based therapeutics. Register today!